Scout Investments Inc. purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 441,156 shares of the specialty pharmaceutical company’s stock, valued at approximately $54,686,000. Jazz Pharmaceuticals comprises approximately 1.4% of Scout Investments Inc.’s investment portfolio, making the stock its 12th largest position.
Several other institutional investors have also made changes to their positions in the company. FMR LLC lifted its stake in Jazz Pharmaceuticals by 12.1% during the 2nd quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after acquiring an additional 715,595 shares in the last quarter. AQR Capital Management LLC lifted its stake in Jazz Pharmaceuticals by 156.6% during the 3rd quarter. AQR Capital Management LLC now owns 344,313 shares of the specialty pharmaceutical company’s stock worth $57,889,000 after acquiring an additional 210,156 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Jazz Pharmaceuticals by 14.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after acquiring an additional 207,954 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Jazz Pharmaceuticals by 1,894.1% during the 3rd quarter. Victory Capital Management Inc. now owns 202,000 shares of the specialty pharmaceutical company’s stock worth $33,962,000 after acquiring an additional 191,870 shares in the last quarter. Finally, Martingale Asset Management L P lifted its stake in Jazz Pharmaceuticals by 10,786.8% during the 3rd quarter. Martingale Asset Management L P now owns 174,516 shares of the specialty pharmaceutical company’s stock worth $29,342,000 after acquiring an additional 172,913 shares in the last quarter. 90.94% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Suzanne Sawochka Hooper sold 3,334 shares of the stock in a transaction dated Friday, December 14th. The stock was sold at an average price of $140.21, for a total value of $467,460.14. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction dated Tuesday, November 13th. The shares were sold at an average price of $149.27, for a total value of $29,854.00. Following the completion of the transaction, the executive vice president now owns 24,972 shares in the company, valued at approximately $3,727,570.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,234 shares of company stock worth $920,255. Company insiders own 3.90% of the company’s stock.
Several equities analysts recently issued reports on JAZZ shares. Cantor Fitzgerald set a $201.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, January 4th. BidaskClub raised Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 18th. Oppenheimer set a $180.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, December 23rd. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, November 7th. Finally, Piper Jaffray Companies set a $208.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 7th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $189.22.
JAZZ stock traded down $1.63 during mid-day trading on Friday, reaching $128.85. The company had a trading volume of 497,959 shares, compared to its average volume of 722,845. Jazz Pharmaceuticals PLC has a fifty-two week low of $113.52 and a fifty-two week high of $184.00. The firm has a market capitalization of $7.92 billion, a P/E ratio of 13.48, a P/E/G ratio of 0.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.29 and a quick ratio of 4.16.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating analysts’ consensus estimates of $3.32 by $0.26. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. The business had revenue of $469.37 million for the quarter, compared to the consensus estimate of $482.64 million. During the same quarter in the prior year, the business posted $3.22 EPS. The business’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, analysts expect that Jazz Pharmaceuticals PLC will post 11.63 EPS for the current year.
WARNING: “Scout Investments Inc. Purchases Shares of 441,156 Jazz Pharmaceuticals PLC (JAZZ)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://transcriptdaily.com/2019/01/12/scout-investments-inc-purchases-shares-of-441156-jazz-pharmaceuticals-plc-jazz.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: What are different types of coverage ratios?
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.